Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 263

1.

Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.

Ross JS, Badve S, Wang K, Sheehan CE, Boguniewicz AB, Otto GA, Yelensky R, Lipson D, Ali S, Morosini D, Chliemlecki J, Elvin JA, Miller VA, Stephens PJ.

Arch Pathol Lab Med. 2015 May;139(5):642-9. doi: 10.5858/arpa.2014-0200-OA.

2.

A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.

Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L.

Oncologist. 2014 May;19(5):453-8. doi: 10.1634/theoncologist.2013-0377. Epub 2014 Apr 7.

3.

Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.

Ross JS, Gay LM, Nozad S, Wang K, Ali SM, Boguniewicz A, Khaira D, Johnson A, Elvin JA, Vergilio JA, Suh J, Miller VA, Stephens PJ.

Breast Cancer Res Treat. 2016 Jan;155(2):405-13. doi: 10.1007/s10549-016-3682-6. Epub 2016 Jan 13.

PMID:
26762307
4.

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.

Ross JS, Wang K, Al-Rohil RN, Nazeer T, Sheehan CE, Otto GA, He J, Palmer G, Yelensky R, Lipson D, Ali S, Balasubramanian S, Curran JA, Garcia L, Mahoney K, Downing SR, Hawryluk M, Miller VA, Stephens PJ.

Mod Pathol. 2014 Feb;27(2):271-80. doi: 10.1038/modpathol.2013.135. Epub 2013 Jul 26.

5.

Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.

Ross JS, Wang K, Rand JV, Sheehan CE, Jennings TA, Al-Rohil RN, Otto GA, Curran JC, Palmer G, Downing SR, Yelensky R, Lipson D, Balasubramanian S, Garcia L, Mahoney K, Ali SM, Miller VA, Stephens PJ.

Am J Surg Pathol. 2014 Feb;38(2):235-8. doi: 10.1097/PAS.0000000000000102.

PMID:
24418857
6.

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.

Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, Stephens PJ.

Cancer. 2016 Sep 1;122(17):2654-62. doi: 10.1002/cncr.30102. Epub 2016 Jun 10.

7.

Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.

Ross JS, Wang K, Sheehan CE, Boguniewicz AB, Otto G, Downing SR, Sun J, He J, Curran JA, Ali S, Yelensky R, Lipson D, Palmer G, Miller VA, Stephens PJ.

Clin Cancer Res. 2013 May 15;19(10):2668-76. doi: 10.1158/1078-0432.CCR-13-0295. Epub 2013 Apr 10.

8.

Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.

Ali SM, Pal SK, Wang K, Palma NA, Sanford E, Bailey M, He J, Elvin JA, Chmielecki J, Squillace R, Dow E, Morosini D, Buell J, Yelensky R, Lipson D, Frampton GM, Howley P, Ross JS, Stephens PJ, Miller VA.

Oncologist. 2016 Jan;21(1):33-9. doi: 10.1634/theoncologist.2015-0241. Epub 2015 Dec 15.

9.

Concordance of genomic alterations between primary and recurrent breast cancer.

Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, PĂ©rez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, Gonzalez-Angulo AM.

Mol Cancer Ther. 2014 May;13(5):1382-9. doi: 10.1158/1535-7163.MCT-13-0482. Epub 2014 Mar 7.

10.

Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.

Ross JS, Ali SM, Wang K, Khaira D, Palma NA, Chmielecki J, Palmer GA, Morosini D, Elvin JA, Fernandez SV, Miller VA, Stephens PJ, Cristofanilli M.

Breast Cancer Res Treat. 2015 Nov;154(1):155-62. doi: 10.1007/s10549-015-3592-z. Epub 2015 Oct 12.

PMID:
26458824
11.

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA.

Eur Urol. 2013 May;63(5):920-6. doi: 10.1016/j.eururo.2012.08.053. Epub 2012 Sep 5.

12.

Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.

Al-Rohil RN, Tarasen AJ, Carlson JA, Wang K, Johnson A, Yelensky R, Lipson D, Elvin JA, Vergilio JA, Ali SM, Suh J, Miller VA, Stephens PJ, Ganesan P, Janku F, Karp DD, Subbiah V, Mihm MC, Ross JS.

Cancer. 2016 Jan 15;122(2):249-57. doi: 10.1002/cncr.29738. Epub 2015 Oct 19.

13.

Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.

Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, Miller VA, Zajchowski D, Shawver LK, Stephens PJ.

Gynecol Oncol. 2013 Sep;130(3):554-9. doi: 10.1016/j.ygyno.2013.06.019. Epub 2013 Jun 20.

14.

Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.

Lim SM, Kim EY, Kim HR, Ali SM, Greenbowe JR, Shim HS, Chang H, Lim S, Paik S, Cho BC.

Oncotarget. 2016 Apr 26;7(17):24172-8. doi: 10.18632/oncotarget.8138.

15.

Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.

Young G, Wang K, He J, Otto G, Hawryluk M, Zwirco Z, Brennan T, Nahas M, Donahue A, Yelensky R, Lipson D, Sheehan CE, Boguniewicz AB, Stephens PJ, Miller VA, Ross JS.

Cancer Cytopathol. 2013 Dec;121(12):688-94. doi: 10.1002/cncy.21338. Epub 2013 Jul 24.

16.

Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.

Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, Kris MG, Ladanyi M, Rizvi NA.

Clin Cancer Res. 2015 Aug 15;21(16):3631-9. doi: 10.1158/1078-0432.CCR-14-2683. Epub 2015 Jan 7.

17.

A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.

Ross JS, Wang K, Gay LM, Al-Rohil RN, Nazeer T, Sheehan CE, Jennings TA, Otto GA, Donahue A, He J, Palmer G, Ali S, Nahas M, Young G, Labrecque E, Frampton G, Erlich R, Curran JA, Brennan K, Downing SR, Yelensky R, Lipson D, Hawryluk M, Miller VA, Stephens PJ.

Clin Cancer Res. 2014 Jan 1;20(1):68-75. doi: 10.1158/1078-0432.CCR-13-1992. Epub 2013 Nov 5.

18.

Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.

Ross JS, Wang K, Rand JV, Gay L, Presta MJ, Sheehan CE, Ali SM, Elvin JA, Labrecque E, Hiemstra C, Buell J, Otto GA, Yelensky R, Lipson D, Morosini D, Chmielecki J, Miller VA, Stephens PJ.

J Clin Pathol. 2014 Nov;67(11):968-73. doi: 10.1136/jclinpath-2014-202514. Epub 2014 Jul 30.

19.

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

Ali SM, Sanford EM, Klempner SJ, Rubinson DA, Wang K, Palma NA, Chmielecki J, Yelensky R, Palmer GA, Morosini D, Lipson D, Catenacci DV, Braiteh F, Erlich R, Stephens PJ, Ross JS, Ou SH, Miller VA.

Oncologist. 2015 May;20(5):499-507. doi: 10.1634/theoncologist.2014-0378. Epub 2015 Apr 16.

20.

Comprehensive genomic profiling of malignant phyllodes tumors of the breast.

Nozad S, Sheehan CE, Gay LM, Elvin JA, Vergilio JA, Suh J, Ramkissoon S, Schrock AB, Hirshfield KM, Ali N, Ganesan S, Ali SM, Miller VA, Stephens PJ, Ross JS, Chung JH.

Breast Cancer Res Treat. 2017 Apr;162(3):597-602. doi: 10.1007/s10549-017-4156-1. Epub 2017 Feb 17.

PMID:
28210881

Supplemental Content

Support Center